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 We investigated the clinical symptom profiles of carriers of the schizophrenia mir137 risk 
allele.  
 The sample included 821 patients with schizophrenia, schizoaffective disorder and bipolar I 
disorder. 
 Risk allele carriers had lower scores for positive symptoms and less psychosis incongruity. 
 On neurocognitive testing in a subset, there were more cognitive deficits in risk allele 
carriers 
*Highlights (for review)
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OBJECTIVE: The Schizophrenia Psychiatric Genome-wide Association (GWAS) Consortium recently 
reported on five novel schizophrenia susceptibility loci. The most significant finding mapped to a 
micro-RNA, MIR-137, which may be involved in regulating the function of other schizophrenia and 
bipolar disorder susceptibility genes. METHOD: We genotyped 821 patients with confirmed DSM-IV 
diagnoses of schizophrenia, bipolar affective Disorder I and schizoaffective disorder for the risk SNP 
(rs1625579) and investigated the clinical profiles of risk allele carriers using a within-case design. We 
also assessed neurocognitive performance in a subset of cases (n=399) and controls (n=171). 
RESULTS: Carriers of the risk allele had lower scores for an OPCRIT-derived positive symptom factor 
(p=0.04) and lower scores on a lifetime measure of psychosis incongruity (p=0.017). Risk allele 
carriers also had more cognitive deficits involving episodic memory and attentional control. 
CONCLUSION: This is the first evidence that the MIR-137 risk variant may be associated with a 
specific subgroup of psychosis patients. Although the effect of this single SNP was not clinically 
relevant, investigation of the impact of carrying multiple risk SNPs in the MIR-137 regulatory 
network on diagnosis and illness profile may be warranted.  
 
Introduction: 
The Schizophrenia Psychiatric Genome-Wide Association (GWAS) Consortium recently reported on 
the largest molecular genetic investigation of schizophrenia to date [9] . The study, a meta-analysis of 
GWAS data, included 9,394 cases and 12,462 controls; top loci were than evaluated in a replication 
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sample of 8,442 cases and 21,397 controls. This confirmed two previously identified risk loci and 
identified five novel loci, of which the most significant finding mapped to a single nucleotide 
polymorphism (SNP) (rs1625579; p=1.6×10-11) within the precursor for microRNA 137 (MIR-137), a 
known regulator of neuronal development [9]. The odds ratio for this risk allele was found to be 1.12. 
The study adds to a growing list of common and rare genetic risk variants being implicated in 
schizophrenia susceptibility, although most of the population variance in risk is yet to be explained 
[22].  
A key question, which has both diagnostic and therapeutic implications, is whether schizophrenia 
etiology involves one or many different molecular risk mechanisms. Although the associated ‘T’ 
allele at SNP rs1625579 has a modest overall effect on schizophrenia risk (OR=1.12), it is of interest 
as it may implicate a particular molecular risk mechanism. MicroRNAs (miRNAs) are small non-
coding RNAs that play a regulatory role in cellular processes, including brain functioning, by 
regulating the function of potentially hundreds of genes through RNA interference. MIR-137 has 
been directly implicated in regulation of neuronal maturation [17] and adult neurogenesis [16,18]. In 
the Psychiatric GWAS Consortium (PGC) study 9 , SNPs mapping to the 301 high-confidence predicted 
gene targets of MIR-137 were more likely to be associated with schizophrenia than would be 
expected by chance. Gene targets of MIR-137 include the bipolar disorder susceptibility gene 
CACNA1C, suggesting that MIR-137 mechanism may have a wider impact on psychosis risk. A small 
GWAS study by Potkin and colleagues [15] reported modest association between genetic variants in 
the gene network regulated by MIR-137 and reduced dorsolateral prefrontal cortex (DLPFC) 
activation during a working memory task. Predicted target genes of MIR-137 include 4 genes which 
have reached genome-wide significance in schizophrenia studies, namely CSMD1, C10orf26, 
CACNA1C and TCF4 [12]. There has not been evidence to date of altered MIR-137 expression in either 
peripheral tissue or brain tissue in individuals with schizophrenia [3]. 
The wealth of evidence supporting overlap of heritability across schizophrenia, bipolar disorder and 
schizoaffective disorder [13],  [19+ taken with the identification of the psychiatric diagnosis as “the 
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weak component of modern research” *1], the overlap of symptoms across diagnostic entities, and 
the differing clinical manifestations of each individual diagnosis throws into relief longstanding 
debates over the validity of Kraepelin’s dichotomy *11]. A convincing argument has been made for 
the use of more complex models [6] in psychiatric research, to avert the problems associated with a 
categorical diagnostic approach, which lose information regarding symptomatic experience of 
illness.  
The aim of this study was to investigate whether carriers of the risk allele at MIR-137 represented a 
specific psychosis subgroup as defined by clinical or neuropsychological features. To test this 
hypothesis we examined clinical profiles of psychosis patients (n=821) using a within case design to 
determine if carriers of the MIR-137 risk allele (rs1625579) had different symptom profiles. Using a 
dimensional approach facilitated the inclusion of subjects with bipolar disorder and schizoaffective 
diagnoses, as the dimensional approach favours the capture of subtle differences in clinical 
manifestations both within and across diagnostic categories. 
We also assessed whether carrying this allele was associated with differences in neurocognitive 
performance in a subset of cases (n=399) and controls subjects (n=171).  
 
Methods: 
Subjects and Assessment: 
Subjects were recruited through community and inpatient mental health facilities throughout the 
island of Ireland for genetic studies of psychotic disorders. The sample was a convenience sample. 
Treating teams nominated potential participants, who were then invited to meet researchers. 
Where individuals were identified in an acute phase of their illness, interview was deferred. 
Approximately 20% of nominated participants declined to partake. Of the 902 participants recruited 
by the time of this analysis, 81 were excluded from further analysis (diagnoses of delusional 
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disorder, OCD, intellectual disability, epilepsy, bipolar affective disorder II, psychotic disorder not 
otherwise specified). All participants provided written informed consent and were interviewed using 
the Structured Clinical Interview for DSM-IV Axis 1 Diagnoses (SCID) [8] . Diagnosis of a major 
psychotic disorder was made by the consensus lifetime best estimate method using DSM-IV criteria 
with all available information- interview, the Operational Criteria Checklist for Psychotic Illness 
(OPCRIT) [14], family or staff report, and chart review. All cases were over 18 years of age, of Irish 
origin (with 4 Irish grandparents) and had been screened to exclude substance-induced psychotic 
disorder or psychosis due to a general medical condition. The current study included 821 patients 
with a DSM-IV diagnosis of schizophrenia (N=573), schizoaffective disorder (N=123) or bipolar 
affective disorder I (N=125).  Further demographic details on subjects have been published 
elsewhere [10].   
The sample for neurocognitive testing consisted of 399 cases and 171 controls. Cases consisted of 
clinically stable patients with a DSM-IV diagnosis of SZ (n=329) or schizoaffective disorder (n=70) 
recruited from 5 sites across Ireland. Other clinical characteristics of the clinical sample are detailed 
elsewhere. [20] 
 
The healthy control sample was recruited on the basis of responses to local media advertisements. 
Control participants were only included if they were aged between 18 and 65 and satisfied, based on 
clinical interview, the criteria of having no history of major mental health problems, intellectual 
disability or acquired brain injury, and no history of substance misuse in the preceding six months 
based on self report. Control participants were also excluded from the study if they reported having 
a 1st degree relative with a history of psychosis.   
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The Bipolar Affective Disorder Dimension Scale (BADDS), developed by Craddock and colleagues [5] 
as an adjunct to conventional categorical diagnosis, was used as an additional measure of lifetime 
symptomatology, in order to capture a more complete description of frequency and severity 
affective and psychotic episodes, which can be lost in hierarchical diagnoses. The BADDS scale 
provides a measure of severity over the course of illness for Manic, Depressive, Psychotic, 
Incongruent dimensions. The four dimensions- Mania, Depression, Psychosis and Incongruence are 
each rated as an integer on a 0 – 100 scale.  The range within which the score lies is informed by the 
severity of the worst episode, and within that range it is determined by the number of episodes. 
Anchor points are clearly defined. For example, an individual who has experienced a number of 
hypomanic episodes, but no manic episodes, would score between 40 and 59 in the mania 
dimension, depending on the number of episodes. An extra point is scored for the number of similar 
episodes, while half a point would be added for each less severe episode.  
 
The BADDS is a particularly useful instrument as it is able to accommodate sub-clinical features, 
discriminates between illness severity within disease category and show similarities in course of 
illness in individuals within different disease categories. The initial validation study included subjects 
with schizophrenia [5], and a further reliability study has been completed in schizoaffective disorder 
[21] 
 
The operational criteria checklist for psychotic illness (Opcrit) was developed, by McGuffin and 
Farmer [14], as a computer suite of programmes to facilitate a polydiagnostic approach. It involves a 
90 item checklist. 30 items relate to background information, while 60 items apply to the presence 
or otherwise of clinical features or symptoms. Scoring is typically between 0 and 2, with 1 typically 
indicating a symptom having been present for no more than a few days.  
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Neuropsychological assessment focused on the domains of (1) general cognitive ability (IQ) as 
measured by an abbreviated version of the Wechsler Adult Intelligence Scale (WAIS-III); (2) verbal 
episodic and working memory as measured by the Logical Memory (LM), Letter Number Sequencing 
(LNS), and digit span sub-tests from the Wechsler Memory Scales (WMS-III); (3) spatial episodic and 
working memory as assessed using the CANTAB paired associate learning task and the Spatial 
Working Memory task; and (4) attentional control as assessed using the CPT-IP. Further details on 
the neuropsychological assessment are reported elsewhere by Walters et al [20]. 
  
Genotyping  
The SNP rs1625579, was genotyped using a Taqman® SNP Genotyping Assay on a 7900HT Sequence 
Detection System (Applied Biosystems). The call rate for was >95%. Both case/control samples were 
in Hardy-Weinberg Equilibrium (HWE; p>0.05). A number of HapMap CEU DNA samples (n=90: 
www.hapmap.org) were genotyped for quality control purposes. All genotypes were found to be 
concordant with available online HapMap data. 
 
Statistical Analysis 
The risk ‘T’ allele is common, but because there is insufficient basis to test a specific genetic model 
(e.g. dominant or recessive) our primary analysis was based on all three genotype groups TT (n=547), 
TG (n=231) and GG (n=26). Where significant differences were detected these were further explored 
in a two-group analysis of homozygous ‘T’ risk allele carriers versus carriers of 1 or 0 risk alleles.  
We investigated for association between rs1625579, and demographic variables which could 
potentially have relationships with lifetime dimension scores, using Chi-squared tests and ANOVAS. 
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ANOVAS were performed examining for interactions between each genotype group and each of the 
four BADDS dimension scores for Manic, Depressive, Psychotic and Incongruent symptoms. For the 
factor analysis, we selected the 60 signs and symptoms within the Operational Criteria Checklist for 
Psychotic Illness (OPCRIT) to enter into exploratory factor analysis with VARIMAX rotation, using 
SPSS 16.0. Variables not directly associated with phenomenology (e.g. source of rating, duration of 
illness) were excluded. We used the scree plot, displayed in supplementary Figure 1 to determine 
the number of factors that best accounted for the covariance among these items. We selected items 
with loadings of 0.4 or greater to create factor-derived scales, yielding 44 items. A five factor 
solution gave an interpretable pattern of factors, namely manic, depressive, positive, disorganized 
and negative factors. These five factors accounted for 47.58% of the total variance. The Kaiser-
Meyer-Olkin Measure of Sampling Adequacy was 0.856, sufficient for a satisfactory factor analysis to 
proceed. Bartlett’s test of sphericity was 14958.995, p<0.0001. Factor score coefficients were then 
calculated in SPSS 16.0 using the regression method. Having derived the factor scores, we then 
performed MANOVAs looking for an association between SNP rs1625579 status and each of the five 
identified factors.  
Association between MIR-137 rs1625579 and the phenotypes of general cognitive function, episodic 
memory, working memory and attentional control were tested using a general factorial design in the 
same statistical package. Our analysis was based on a comparison of the three genotype groups (TT 
versus TG versus GG) and diagnosis (cases versus controls), both of which were entered as fixed 
effects. In a series of ANCOVAs scores for each neuropsychological subtest were entered as the 
dependent variables, with age and gender included as covariates where appropriate.  
 
Results: 
Page 10 of 17
Ac
ce
pte
d M
an
us
cri
pt
9 
 
The final clinical analysis included 803 cases who passed genotyping QC. Demographic and clinical 
characteristics by rs1625579 genotype (TT, GT, GG) appear in Table 1. There was no association 
between the risk SNP and diagnosis (schizophrenia, schizoaffective disorder or bipolar disorder), 
current age, gender, or medication dosage in chlorpromazine equivalents (Supplementary Table 1). 
The risk allele for SNP rs1625579 was associated with lower BADDS Incongruence dimension scores 
(p=0.017) as well as lower OPCRIT-derived positive symptom scores (p=0.041). When analyses of the 
relationship between the BADDS incongruence groups were restricted to diagnostic groups, the 
signal was strongest amongst those with a diagnosis of bipolar disorder (p=0.024, partial eta 
squared=0.060). These findings were confirmed in a two-group analysis, where having two copies of 
the risk allele was associated with significantly lower Incongruence dimension (p=0.019) and positive 
symptom factor (p=0.015)  scores, compared with having one or no copies of the risk allele in this 
psychosis sample. Partial eta squared for both scores is 0.007. The relationship between genotype 
and the scores for these measures (shown in Figure 1) suggests an allele dosage effect.  
 
Mean scores for each of the four cognitive domains (IQ, working memory, episodic memory and 
attention) by MIR-137 genotype group for cases and controls are presented in Table 2. As expected, 
patients performed below controls on all cognitive tests administered (p<0.0001). MIR-137 genotype 
was not associated with differences in IQ, either as a main effect or as an interaction effect with 
case-control status. Analysis of the three allele groups (TT, GT, GG) identified association between 
groups carrying ‘T’ risk allele and verbal episodic memory (Logical Memory, Immediate; F=1.16, 
p=0.048) and extradimensional set shifting (as measured by the IDED-ED scores) attentional control 
phenotypes; F=3.23, p=0.04). In each case carrying the risk allele was associated with worse 
performance; there was no interaction effect with case/control status. Given the small number of 
homozygous risk carriers, these were repeated in a two-group analysis comparing the homozygous 
carriers of the ‘T’ risk allele with all other patients; both findings were confirmed.  
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Discussion: 
A common genetic variant at MIR-137 has recently emerged as a risk factor for schizophrenia. We 
investigated the role of the MIR-137 risk SNP (rs1625579) on psychosis symptom factors and 
dimensional measures of lifetime symptomatology. We identified association between the ‘T’ risk 
allele and lower scores for an OPCRIT-derived psychotic symptom factor. Carriers of the risk allele 
also scored lower on a lifetime measure of psychosis-symptom incongruity. This finding suggests 
that carriers of the MIR-137 risk allele are more likely to represent a subgroup of psychotic patients 
with fewer psychotic symptoms, where these symptoms are mood-congruent. There was no 
converse finding of an increased burden of negative symptoms, and there was no evidence that the 
variant influenced mood symptomatology directly within our cohort. One possible explanation is 
that this group represents patients defined by a particular molecular aetiology. Alternatively, the risk 
variant may have a modifying effect which increases risk of mood congruent psychotic symptoms 
among psychosis-spectrum patients, where psychotic symptoms are experienced. 
While cognitive deficits are less prominent in bipolar disorder than in schizophrenia, where both 
global and specific cognitive deficits are described, a range of abnormalities have been reported 
including deficits in episodic and working memory, processing speed and sustained attention [2,4]. 
The cognitive deficits associated with MIR-137 in this study affected domains reported to be 
impaired in both disorders.  Specifically, risk allele carriers did not show deficits in global function as 
measured by IQ, but did show subtle deficits in both episodic memory and attentional control. In 
both cases, the deficits were more prominent in a 2-groups comparison of homozygous risk carriers 
versus the other genotype groups combined. Previous work by our group suggested that deficits in 
attentional control disassociate from more general cognitive deficits within the schizophrenia 
population [7]. Whether the subtlety of these effects reflects this risk variant’s particular association 
with an affective form of psychosis in which cognitive deficits are less pronounced, or simply reflect 
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the modest cognitive effects of this variant  remains to be elucidated. Further studies, incorporating 
functional MRI may be helpful in establishing the true strength of this effect.  
Multiple statistical tests were performed in this study and the findings could reflect Type 1 errors. 
However, although a relatively large clinical sample (n=831), our study was significantly 
underpowered to detect subtle clinical effects compared to large GWAS samples such as the PGC. 
We tried to control for the temporal instability of clinical symptomatology by using two different 
measures of psychopathology in a cohort of psychosis patients with generally well-established illness 
(mean duration of illness 19 years, SD 12 years). One measure captured the life-time presence of 
different symptoms (OPCRIT), while the other measured severity and frequency of illness episodes 
over time. Our psychosis sample was over-represented for schizophrenia cases (n=573) and the life-
time measure employed (BADDSS) was developed and validated for use in bipolar disorder subjects. 
Further studies using serial assessment of clinical symptoms and neurocognitive performance are 
warranted.  
It is important to note that MIR-137 genotype was responsible for <1% of the variance in scores 
(based on the associated partial eta squared values) on the incongruity dimension and psychosis 
factor. This indicates that the common risk variant at MIR-137 does not have a clinically meaningful 
effect on either symptom profile or cognitive performance. In the Psychiatric GWAS Consortium 
(PGC) study, SNPs mapping to the 301 high-confidence predicted gene targets of MIR-137 were 
enriched for association signals with schizophrenia, compared with other genes of similar size or 
genetic marker density in the genome. Excluding the gene itself and the major histocompatibility 
complex region (MHC), 4 of 9 associated loci in a combined meta-analysis of schizophrenia and 
bipolar GWAS data had predicted MIR-137 target sites, ie  TCF4, CACNA1C, CSMD1 and C10orf26 [9].  
Further questions raised by this study, are whether having a greater burden of common risk variants 
from this gene network is associated with increased illness risk, the extent of this risk, and whether 
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this maps a molecular subtype of psychosis characterized by less psychotic or incongruent psychotic 
symptomatology and subtle cognitive deficits. 
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Figure 1 Relationships between genotype groups and Opcrit-derived positive symptom factor score, Bipolar Affective 
Disorder Incongruence Dimension Score 
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Table 1 RS1625579 SNP Genotype Groups and Demographic Variables 
 
 
 
GG (n=26) 
Mean 
(SD) 
TG (n=231) 
Mean 
(SD) 
TT (n=547) 
Mean 
(SD) 
F/ X² 
value 
P value 
Age at Onset  
 
 
21.17 
(7.069) 
24.23 
(8.297) 
24.03 
(8.476) 
1.388 .250 
Duration of 
Illness 
(Years) 
 
14.9148 
(15.43135) 
19.9946 
(12.26666) 
19.9617  
(12.30284) 
1.850 .158 
Chlorpromazine 
Equivalent (mg) 
 
412 
(412.838) 
506.86 
(449.29) 
468.86 
(411.856) 
.730 .483 
Gender (% 
Male) 
 
 
84.0% 62.67% 66.16% 4.683 0.096 
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RS1625579 (PGC1) stats results table (2 groups) 
Cognitive 
function 
Test or 
Subscale sample n Mean (SD) Mean (SD) 
FCase v 
Controls p 
FMain 
effect p 
FInteraction 
effect p 
        GG/GT TT             
IQ 
 
Abbreviated Full 
Scale IQ 
Patients 
Controls 
275 
133 
93.31(17.82) 
124.33(12.2) 
90.63(17.19) 
121.82(15.4) 293.1 <.0001 2.384 .123 .410 .522 
 
WTAR (Adult 
reading test) 
Patients 
Controls 
275 
133 
96.45(11.93) 
110.06(3.73) 
97.32(11.32) 
109.55(5.34) .012 <.0001 .012 .461 0 .985 
 Verbal IQ 
Patients 
Controls 
275 
133 
94.06(16.02) 
125.79(13.8) 
93.03(17.51) 
123.7(14.99) 282.1 <.0001 .817 .367 .079 .778 
 Performance IQ 
Patients 
Controls 
275 
133 
93.75(20.8) 
119.33(13.5) 
89.71(18.59) 
116.03(19.3) 173.4 <.0001 3.04 .051 .099 .753 
            
Working 
Memory 
LN sequence 
 
Patients 
Controls 
370 
167 
8.162(3.548) 
13.38(2.91) 
7.51(3.24) 
12.78(3.34) .014 .924 1940 .014 .005 .956 
 
CANTAB SWM 
(Between error) 
Patients 
Controls 
366 
159 
-.80(1.32) 
.237(.716) 
-1.02(1.3) 
.281(.823) 96.98 <.0001 .628 .149 1.186 .277 
            
Episodic 
Memory 
Logical Memory 
Immediate 
Patients 
Controls 
379 
167 
7.01(3.52) 
12.75(2.54) 
6.18(3.31) 
12.72(2.95) 346.2 <.0001 1.535 .023 1.72 .19 
 
Logical Memory 
Delayed 
Patients 
Controls 
379 
167 
7.46(3.19) 
13.29(2.4) 
7.21(3.21) 
13.34(2.65) 369.1 <.0001 .035 .244 .354 .552 
 
CANTAB PAL 
(Adjusted 
Standard score) 
Patients 
Controls 
291 
123 
-2.65(3.84) 
.1592(1.2) 
-2.77(3.77) 
.2654(1.08) 53.89 <.0001 .001 .297 .092 .762 
 Faces 1 
Patients 
Controls 
355 
168 
8.69(2.83 
11.14(2.64) 
8.76(2.77) 
11.54(2.88) 85.1 <.0001 .221 .639 .031 .861 
 Faces2 
Patients 
Controls 
355 
168 
9.2(2.86) 
11(2.46) 
9.34(2.93) 
11.63(2.84) 46.5 <.0001 2.054 .152 .845 .358 
            
Vigilant 
attention 
CPT_IP 
(3 letters) 
Patients  
Controls 
74 
0 
1.85(1.01) 
 
2.02(.973) 
 
---- ---- 
1.457 .229 
---- ---- 
 
IDED (8 shapes 
adjusted) 
Patients 
Controls 
322 
157 
10.85(10.65) 
7.05(7.95) 
12.93(10.97) 
9.39(10.15) 
17.85 <.0001 
 
5.16 
.047 .042 .838 
 
IDED (6 shapes 
adjusted)) 
Patients 
Controls 
322 
157 
1.05(2.85) 
.381(.652) 
.812(1.49) 
.814(2.3) 
2.53 .112 
 
.204 
.652 2.738 .099 
            
 
Table
